FAG
JAZZ icon

Fortitude Advisory Group’s Jazz Pharmaceuticals JAZZ Stock Holding History

Fortitude Advisory Group’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-152
Closed -$24K – 744
2022
Q1 		$24K Hold
152
– – 0.01% 771
2021
Q4 		$19K Buy
+152
New +$20K 0.01% 860

Other funds holding JAZZ

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
PCM
Polaris Capital Management Boston, Massachusetts $1.06B AUM 40.82% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
SC
Samlyn Capital New York $6.14B AUM 42.05% 1-Year Est. Return

Fortitude Advisory Group's JAZZ Position: Q2 2022 in Review

Fortitude Advisory Group sold out of Jazz Pharmaceuticals (JAZZ) in Q2 2022, closing a stake of 152 shares — an estimated $24K sold.

Fortitude Advisory Group first reported a position in JAZZ in Q4 2021 and held it in 2 quarters. The position peaked at $24K in Q1 2022. 468 funds tracked by Wall St. Rank hold JAZZ as of Q2 2022.

  • Fortitude Advisory Group reported no remaining Jazz Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • Fortitude Advisory Group sold 152 Jazz Pharmaceuticals shares in Q2 2022, an estimated $24K.
  • Fortitude Advisory Group first reported a position in Jazz Pharmaceuticals in Q4 2021 and held it in 2 quarters.
  • Fortitude Advisory Group's Jazz Pharmaceuticals position peaked at $24K in Q1 2022.
  • 468 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2022.

Based on Fortitude Advisory Group's 13F filing for Q2 2022, filed 16 Aug 2022.